BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35879722)

  • 21. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
    Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy.
    Chennupati SK; Pelizzari CA; Kunnavakkam R; Liauw SL
    Cancer Med; 2014 Aug; 3(4):954-61. PubMed ID: 24803087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
    Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    Miller LE; Efstathiou JA; Bhattacharyya SK; Payne HA; Woodward E; Pinkawa M
    JAMA Netw Open; 2020 Jun; 3(6):e208221. PubMed ID: 32585020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
    Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
    Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
    Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
    Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
    Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial.
    Monninkhof EM; van Loon JWL; van Vulpen M; Kerkmeijer LGW; Pos FJ; Haustermans K; van den Bergh L; Isebaert S; McColl GM; Smeenk RJ; Noteboom J; Walraven I; Peeters PHM; van der Heide UA
    Radiother Oncol; 2018 Apr; 127(1):74-80. PubMed ID: 29336835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Late toxicity rates following definitive radiotherapy for prostate cancer.
    Ohri N; Dicker AP; Showalter TN
    Can J Urol; 2012 Aug; 19(4):6373-80. PubMed ID: 22892261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial.
    Murthy V; Maitre P; Bhatia J; Kannan S; Krishnatry R; Prakash G; Bakshi G; Pal M; Menon S; Mahantshetty U
    Radiother Oncol; 2020 Apr; 145():71-80. PubMed ID: 31923712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes.
    Chao M; Bolton D; Lim Joon D; Chan Y; Lawrentschuk N; Ho H; Spencer S; Wasiak J; Guerrieri M; Ow D; Troy A; Pham T; Sengupta S; Tan A; McMillan K; Koufogiannis G; Foroudi F; Ng M; Khoo V
    J Med Imaging Radiat Oncol; 2019 Jun; 63(3):415-421. PubMed ID: 30908894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients.
    Lips IM; Dehnad H; van Gils CH; Boeken Kruger AE; van der Heide UA; van Vulpen M
    Radiat Oncol; 2008 May; 3():15. PubMed ID: 18495016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.
    Guckenberger M; Ok S; Polat B; Sweeney RA; Flentje M
    Strahlenther Onkol; 2010 Oct; 186(10):535-43. PubMed ID: 20890743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
    Dutz A; Agolli L; Baumann M; Troost EGC; Krause M; Hölscher T; Löck S
    Acta Oncol; 2019 Jun; 58(6):916-925. PubMed ID: 30882264
    [No Abstract]   [Full Text] [Related]  

  • 37. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data.
    Karsh LI; Gross ET; Pieczonka CM; Aliotta PJ; Skomra CJ; Ponsky LE; Nieh PT; Han M; Hamstra DA; Shore ND
    Urology; 2018 May; 115():39-44. PubMed ID: 29174940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
    Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
    JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Image guided dose escalated prostate radiotherapy: still room to improve.
    Martin JM; Bayley A; Bristow R; Chung P; Gospodarowicz M; Menard C; Milosevic M; Rosewall T; Warde PR; Catton CN
    Radiat Oncol; 2009 Nov; 4():50. PubMed ID: 19887007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.